Professor Ritchlin's basic science research efforts are directed towards understanding the mechanisms that underlie pathologic bone resorption and new bone formation in psoriatic arthritis and rheumatoid arthritis. His Team also developed a new murine translational model of PsO and PsA and they demonstrated that the decline in secondary bile acids are key events in the transition to PsA.
Prof. Ritchlin is the principal investigator on several clinical trials testing the efficacy of anti-TNF agents and other biologic molecules in the treatment of psoriatic and rheumatoid arthritis and ankylosing spondylitis. He directs the NIAMS Accelerated Medicine Partnership Autoimmune Inflammatory Mediated (AMPAIM) Psoriatic Disease Team focused on understanding key pathophysiology events that underlie psoriasis and PsA using advanced technologies such as single cell RNAseq and spatial transcriptomics.
Prof. Ritchlin is the author or co-author of over 300 peer reviewed articles.